Raymond James Remains a Hold on SAGE Therapeutics (SAGE)
Raymond James analyst Danielle Brill maintained a Hold rating on SAGE Therapeutics (SAGE) yesterday. The company’s shares closed last Wednesday at $78.98.
According to TipRanks.com, Brill is a 4-star analyst with an average return of 15.8% and a 55.2% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
SAGE Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $99.00, which is a 32.5% upside from current levels. In a report issued on March 2, Morgan Stanley also maintained a Hold rating on the stock with a $87.00 price target.
See today’s analyst top recommended stocks >>
SAGE Therapeutics’ market cap is currently $4.61B and has a P/E ratio of 6.70. The company has a Price to Book ratio of 2.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Read More on SAGE: